Sobi Receives Approval from Health Canada for Empaveli™ (pegcetacoplan) for the Treatment of Certain Patients with Paroxysmal Nocturnal Hemoglobinuria
PNH is characterized by the destruction of red blood cells (hemolysis) and release of free hemoglobin that can cause thrombosis and require frequent transfusions.
- PNH is characterized by the destruction of red blood cells (hemolysis) and release of free hemoglobin that can cause thrombosis and require frequent transfusions.
- Empaveli is approved in the United States and the United Arab Emirates for the treatment of adults with PNH.
- In Australia, Empaveli is approved for the treatment of adult patients with PNH who have an inadequate response to, or are intolerant of, a C5 inhibitor.
- McKinley C. Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome.